TYRA
Tyra Biosciences Inc.
Company Overview
| Mkt Cap | $815.53M | Price | $33.59 |
| Volume | 564.64K | Change | +3.45% |
| P/E Ratio | -6.8 | Open | $32.75 |
| Revenue | -- | Prev Close | $32.47 |
| Net Income | $-119.9M | 52W Range | $8.75 - $40.65 |
| Div Yield | N/A | Target | $50.30 |
| Overall | 45 | Value | 60 |
| Quality | 31 | Technical | 45 |
No chart data available
About Tyra Biosciences Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Latest News
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Keeps Their Buy Rating on Tyra Bioscience (TYRA)
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and MDxHealth (MDXH)
Analysts Are Bullish on These Healthcare Stocks: Abeona Therapeutics (ABEO), Protara Therapeutics (TARA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (WST), CalciMedica (CALC) and Tyra Bioscience (TYRA)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TYRA | $33.59 | +3.4% | 564.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |